Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-07-13
2000-09-05
Jarvis, William R. A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31445
Patent
active
061143561
ABSTRACT:
Compositons employing and methods utilizing the optically pure (+) isomer of norcisapride are disclosed. This compound has surprisingly been found to be a potent drug for the treatment of disorders of the central nervous system. The compound, (+) norcisapride, has also been found to be a potent antiemetic agent. Finally, the (+) isomer of norcisapride also avoids certain adverse side effects and certain adverse drug interactions.
REFERENCES:
patent: 4962115 (1990-10-01), Van Daele
patent: 5057525 (1991-10-01), Van Daele
patent: 5137896 (1992-08-01), Van Daele
patent: 5712293 (1998-01-01), McCullough et al.
patent: 5739151 (1998-04-01), McCullough et al.
Barnes, N.M., et al, "Identification of 5-HT.sub.3 Recognition Sites in the Ferret Area Postrema," J. Pharm. Pharmacol., 40:586-588 (1988).
Barone, et al., "Bioavailability of Three Oral Dosage Forms of Cisapride, a Gastrointestinal Stimulant Agent," Clinical Pharmacy, 6:640-645 (1987).
Clarke, D.E., et al., "The 5-HT.sub.3 Receptor: Naughty, but Nice," Trends in Pharmacological Sciences, 10:385-386 (1989).
Costall, B. et al., "Emesis Induced by Cisplatin in the Ferret as a Model for the Detection of Anti-Emetic Drugs," Neuropharmacology, 26:1321-1326 (1987).
Craig & Clark, "5-Hydroxytryptamine and Cholinergic Mechanisms in Guinea-pig Ileum," Brit. J. Pharmacol., 96:247 (1989).
Decktor, D.L., et al., "Effect of Metoclopramide, Bethanechol and the Cholecystokinin Receptor Antagonist, L-364, 718, on Gastric Emptying in the Rat," Eur. J. Pharmacol., 147:313-316 (1988).
Dumuis, A., et al., "The Gastrointestinal Prokinetic Benzamide Derivatives are Agontist at the Non-Classical 5-HT Receptor (5-HT.sub.4) Positively Coupled to Adenylate Cyclase in Neurons," N.S. Arch. Pharmacol., 340:403-410 (1989).
Fernandez & Massingham, "Peripheral Receptor Populations Involved in the Regulation of Gastrointestinal Motility and the Pharmacological Actions of Meoclopramide-like Drugs," Life Sci., 36:1-14 (1985).
Frazer, A., et al., "Subtypes of Receptors for Serotonin," Annual Rev. of Pharmacology and Toxicology, 30:307-348 (1990).
Gladziwa, U., et al., "Pharmacokinetics and pharmacodynamics of cisapride in patients undergoing hemodialysis," Clinical Pharmacology, 50:6:673-681 (1991).
Gullikson, G.W., et al., "Relationship of Serotonin-3 Receptor Antagonist Activity to Gastric Emptying and Motor-Stimulating Actions of Prokinetic Drugs in Dogs," J. Pharmacol. Experimen. Therp., 258:(1):103-110 (1991).
Jamali, F., "Enantioselective Aspects of Drug Action and Disposition: Therapeutic Pitfalls," Journal of Pharmaceutical Sciences, 78(9):695-715 (1989).
Krejs, G.J., "Serotonine intestinale, une cible therapeutique," Med. Chir. Dig., 22:7:415-416 (1993).
Lauwers, W., et al., "Identification of a Biliary Metabolite of Cisapride," Biomedical and Environmental Mass Spectrometry, 15:323-328 (1988).
Lavrijsen, K., et al., "The Role of CYP3A4 in the In-Vitro Metabolism of Cisapride in Human Liver Microsomes and In-Vitro and In Vivo Interactions of Cisapride with Co-Administered Drugs," Dept. of Pharmacokinetics and Drug Metabolism, Janssen Research Foundation (1995).
Meuldermans, W., et al., "Excretion and Biotransformation of Cisapride in Dogs and Humans After Oral Administration," Drug Metabolism and Disposition, 16:3: 403-419 (1988).
Milo, R., "Non-Cholinergic, Non-antidopaminergic Treatment of Chronic Digestive Symptoms Suggestive of a Motility Disorder: A Two-Step Pilot Evaluation of Cisapride," Curr. Therapeutic Research, 36:5:1053-1062 (1984).
Nemeth, P.R., "Gastrointestinal motility stimulating drugs and 5-HT receptors or Myenteric Neurons," Eur. J. Pharmacol., 166:387-391 (1989).
Porsius, A.J., et al., "Farmacotoets 6A," Farmacotherapie, 129:9:214-217 (1994).
Reyntjens, A., et al., "Clinical Pharmacological Evidence For Cisapride's Lack of Antidopaminergic or Direct Cholinergic Properties," Current Therapeutic Research, 36:5:1045-1052 (1984).
Schapira, M., et al., "The Current Status of Gastric Prokinetic Drugs," Acta Gastroenterolog. Belg., LIII:446-457 (1990).
Schiavi, G.B. et al., "Identification of Serotonin 5-HT.sub.4 Recognition Sites in the Porcine Caudate Nucleus by Radioligand Binding," Neuropharmacology, 33:543-549 (1994).
Schuurkes, J.A.J., et al., "Motor-Stimulating Properties of Cisapride on Isolated Gastrointestinal Preparations of the Guinea Pig," J. Pharmacol. Exp. Ther., 234:775-783 (1985).
Stacher, G., et al., "Effects of Oral Cisapride on Interdigestive Jejunal Motor Activity, Psychomotor Function, and Side-Effect Profile in Healthy Man," Digestive Diseases and Sciences, 32:11:1223-1230 (1987).
Van Peer, A., et al., "Clinical Pharmacokinetics of Cisapride," Progress in the Treatment of Gastrointestinal Motility Disorders : The Role of Cisapride, Proceedings of a Symposium in Frankfurt Excerpta Medica, pp. 23-29 (1988).
Williams & Burks, "Cisapride Increases Gastric Emptying Without Affecting Small or Large Bowel Transit," Proc. West. Pharmacol. Soc., 28:47-50 (1985).
Zuccato, E. et al., "The Effects of S(-) and R(+) Sulpiride, Metoclopramide, Cisapride and Doperidone on the Small Intestine Suggest DA.sub.2 -Receptors are Involved in the Control of Small Intestinal Transit Time in Rats", Pharmacological Research, 26 2:179-185 (1992).
Burks, T.F., Principles of Pharmacology, 1996, pp. 1093-1100.
Nemeth, P.R. & Gullikson, G.W., Chemical Abstracts, vol. 111, No., 19, Abs. No. 167161a (1989).
Scrip's New Product Review No. 32 Cisapride, PJB Publications Ltd. (Apr. 1989).
Van Daele, G.H.P. et al., "Synthesis of Cisapride, a Gastrointestinal Stimulant Derived From Cis-4-Amino-3-Methoxypiperidine", Drug Development Res., 8:225-232 (1986).
Preechagoon, Y. et al., "Analysis of Cisapride in Neonatral Plasma Using High-Performance Liquid Chromatography with a Base-Stable Column and Fluorescene Detection", J. Chromatography B: Biomedical Applications, 670 (1):139-143 (1995).
Jerussi Thomas P.
McCullough John R.
Jarvis William R. A.
Sepracor Inc.
LandOfFree
Method for treating gastrointestinal disorders using (+) norcisa does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating gastrointestinal disorders using (+) norcisa, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating gastrointestinal disorders using (+) norcisa will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2212476